In settings with a high proportion of non-facility deliveries, provision of misoprostol to pregnant women for self-use in home births has the potential to expand access to uterus-contracting medicines to prevent PPH. A pilot study – the MamaMiso study - implemented at the community level in Uganda examined the safety and feasibility of this model of care.

This one-page document summarizes the study findings which show that misoprostol distributed antenatally for self-administration can be appropriately taken by women delivering at home. For a more in depth understanding of the study, you can read: The MamaMiso study of self-administered misoprostol to prevent bleeding after childbirth in rural Uganda, Weeks et al. BMC Pregnancy and Childbirth 2015.

Jun. 2016
Research Summary
Postpartum Hemorrhage
Gynuity Health Projects


Not all resources are available in all formats. Select language to check availability.